AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate

Pays $200m Upfront

 
• By Ayisha Sharma
  
AstraZeneca And Ionis Have A Track Record of Dealmaking Together • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip